*恭喜浙江省农业科学院俞老师在SCI期刊 Environmental Science and Pollution Research(IF:2.914)上成功发表
*恭喜西安理工大学张老师,环境水利专业,文章成功发表在SCI期刊Environmental Science and Pollution Research上,IF2.914
*恭喜山东交通学院谢老师在SCI期刊APPLIED SURFACE SCIENCE(IF5.15)上成功发表
*恭喜华中科技大学黄老师在SCI期刊 ACS Applied Materials & Interfaces(IF8.456)上成功发表
*恭喜中南大学湘雅医院黄医生在Frontiers in Oncology(IF 4.137)上成功发表
*恭喜复旦大学辛博士在SCI期刊 FEBS LETTERS(IF2.675)上成功发表
*恭喜中南大学陈博士在THIN-WALLED STRUCTURESSCI期刊(IF3.488)上成功发表
*恭喜湖南工学院郭老师在SCI期刊SIMULATION MODELLING PRACTICE AND THEORY(IF2.42)上成功发表
*恭喜东华大学闫老师在SCI期刊Advanced Functional Materials(IF 15.621)上成功发表
*恭喜安徽医科大学肖老师在SCI期刊BMC CELL BIOLOGY(IF 3.485)上成功发表
*恭喜四川大学华西医院谢医生在SCI期刊European Heart Journal: Acute Cardiovascular Care(IF 3.734)上成功发表

0591-83301811

周一~周日, 8:00 - 23:00

13107667616

周一~周日, 8:00 - 23:00

service@editideas.cn

随时欢迎您的来信!

2021年最新SCI期刊影响因子查询系统

期刊名称:
ISSN:
期刊研究方向:
IF范围:
中科院分区:
SCI/SCIE:
是否OA期刊:
排列方式:

CURRENT OPINION IN PHARMACOLOGY 期刊详细信息

基本信息
期刊名称 CURRENT OPINION IN PHARMACOLOGY
CURRENT OPINION IN PHARMACOLOGY
期刊ISSN 1471-4892
期刊官方网站 http://www.journals.elsevier.com/current-opinion-in-pharmacology/
是否OA
出版商 Elsevier BV
出版周期 Bimonthly
始发年份 2001
年文章数 105
最新影响因子 4.768(2021)
中科院SCI期刊分区
大类学科 小类学科 Top 综述
医学2区 PHARMACOLOGY & PHARMACY 药学2区
CiteScore
CiteScore排名 CiteScore SJR SNIP
学科 排名 百分位 5.14 2.296 1.291
Pharmacology, Toxicology and Pharmaceutics
Drug Discovery
9 / 146 93%
Pharmacology, Toxicology and Pharmaceutics
Pharmacology
17 / 300 94%
补充信息
自引率 0.80%
H-index 111
SCI收录状况 Science Citation Index Expanded
官方审稿时间
网友分享审稿时间 数据统计中,敬请期待。
PubMed Central (PML) http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1471-4892%5BISSN%5D
投稿指南
期刊投稿网址 https://www.elsevier.com/journals/current-opinion-in-pharmacology/1471-4892/guide-for-authors#16000
收稿范围
Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.

COPHAR is part of the Current Opinion and Research (CO+RE) suite of journals and is a companion to the new primary research, open access journal, Current Research in Pharmacology and Drug Discovery (CRPHAR).

COPHAR divides the subject of pharmacology into themed sections, each of which is reviewed once a year. The amount of space devoted to each section is related to its importance. Themes include neurosciences; cardiovascular and renal; respiratory; musculoskeletal; cancer; immunomodulation; anti-infectives; new technologies; gastrointestinal; endocrine; and metabolic diseases.

The journal builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health.


Expertise - Expert authors, who are leaders in their field, are invited to write short review articles in which they present recent developments in their subject and provide short annotations to the papers that they think are most relevant.
Comprehensiveness - There are 27 high-impact Current Opinion review journals in a range of subjects from food science to green and sustainable chemistry.
Impact - In addition to a vast readership, Current Opinion titles enjoy high citations, Impact Factors, and CiteScores.


Selection of topics to be reviewed
Section Editors, who are major authorities in the field, are appointed by the Editors of the journal. They divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasised. Section Editors commission reviews from authorities on each topic that they have selected.

Reviews
Authors write short review articles in which they present recent developments in their subject, emphasising the aspects that, in their opinion, are most important. In addition, they provide short annotations to the papers that they consider to be most interesting from all those published in their topic over the previous year.

Editorial Overview
Section Editors write a short overview at the beginning of the section to introduce the reviews and to draw the reader's attention to any particularly interesting developments.

Ethics in Publishing: General Statement

The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.
收录体裁
review 
投稿指南 https://www.elsevier.com/journals/current-opinion-in-pharmacology/1471-4892/guide-for-authors
投稿模板
参考文献格式 https://www.elsevier.com/journals/current-opinion-in-pharmacology/1471-4892/guide-for-authors
编辑信息
近期成功发表案例展示